Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- PHASE3
Clinical Trials Related to Pulmonary Arterial Hypertension
Related studies linked through entity extraction aliases.
Angiogenic Imaging in Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Repeatability of OCT and IV-US in Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- NA
Inspiratory Muscle Training in Pulmonary Hypertension
- Status
- COMPLETED
- Phase
- NA
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
- Status
- COMPLETED
- Phase
- PHASE4
A Mobile Health Intervention in Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- NA
Pilot Study of the Safety and Efficacy of Anakinra in Pulmonary Arterial Hypertension
- Status
- COMPLETED
- Phase
- PHASE1
TRUST-2: Safety and Efficacy of Intravenous Remodulin® in Patients in India With Pulmonary Arterial Hypertension (PAH)
- Status
- COMPLETED
- Phase
- PHASE4
The Effects of Commercial Air Travel on Patients Suffering From Pulmonary Hypertension
- Status
- UNKNOWN
- Phase
- N/A
Stress Echo 2020 - The International Stress Echo Study
- Status
- UNKNOWN
- Phase
- N/A
Impact of Rehabilitation Program on PAH Patients Treated With Macitentan.
- Status
- UNKNOWN
- Phase
- NA
ADAPT - A Patient Registry of the Real-world Use of Orenitram®
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Safety of Transition From Selexipag to Remodulin® Then Oral Treprostinil in Symptomatic Adult PAH
- Status
- WITHDRAWN
- Phase
- PHASE2
Study to Compare Triple Therapy (Oral Treprostinil, Ambrisentan, and Tadalafil) With Dual Therapy (Ambrisentan, Tadalafil, and Placebo) in Subjects With Pulmonary Arterial Hypertension
- Status
- WITHDRAWN
- Phase
- PHASE3
Pulmonary Vascular Disease Phenomics Program PVDOMICS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Study Evaluating the Effects of First-line Oral cOmbination theraPy of maciTentan and tadalafIl in Patients With Newly Diagnosed pulMonary Arterial Hypertension (OPTIMA)
- Status
- TERMINATED
- Phase
- PHASE4
The Effect of Adding Exercise Training to Optimal Therapy in PAH
- Status
- COMPLETED
- Phase
- NA
FDG Uptake and Lung Blood Flow in PAH Before and After Treatment With Ambrisentan
- Status
- WITHDRAWN
- Phase
- NA
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
- Status
- TERMINATED
- Phase
- PHASE2
A Study to Assess Whether Macitentan Delays Disease Progression in Children With Pulmonary Arterial Hypertension (PAH)
- Status
- COMPLETED
- Phase
- PHASE3